Skip to main content
Fig. 1 | Lipids in Health and Disease

Fig. 1

From: Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway

Fig. 1

Inhibition of NAMPT aggravates hepatic lipid accumulation in vivo. FK866 (NAMPT inhibitor, 2 mg/kg/day, IP) was administrated into male C57BL/6 mice for 1 week with normal diet (ND) or high fat diet (HFD) and then, the mice were continually fed with ND or HFD for 12 weeks. a The relative expressions of NAMPT by real-time PCR analysis in liver of the mice. b Quantitative analysis of the expressions of the lipid synthetic genes by RT-PCR in liver from the mice. c The morphological analysis of Hematoxylin and eosin staining in liver from the mice. d The expression of NAMPT in liver from the HFD-fed mice with a NAMPT inhibitor FK866. e Quantitative analysis of NAMPT protein level from western blot bands. f Quantitative analysis of the expressions of the lipid synthetic genes by RT-PCR in liver from the mice. g The images of FASN protein by Western blot analysis in liver from the mice. h Quantitative analysis of FASN protein level from western blot bands. The data represent the mean ± SEM. N = 5, *P < 0.05 and **P < 0.01 versus the control

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X